Knollwood Investment Advisory LLC Increases Stock Position in Eli Lilly and Company $LLY

Knollwood Investment Advisory LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 10.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,599 shares of the company’s stock after acquiring an additional 1,300 shares during the quarter. Eli Lilly and Company comprises approximately 1.0% of Knollwood Investment Advisory LLC’s portfolio, making the stock its 16th biggest holding. Knollwood Investment Advisory LLC’s holdings in Eli Lilly and Company were worth $10,601,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Laurel Wealth Advisors LLC increased its stake in Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. Norges Bank purchased a new position in Eli Lilly and Company in the 2nd quarter worth approximately $8,827,714,000. Nuveen LLC purchased a new position in shares of Eli Lilly and Company in the first quarter valued at $4,613,912,000. Vanguard Group Inc. boosted its position in Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of Eli Lilly and Company by 106.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after purchasing an additional 765,010 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,011.74 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The company has a market cap of $956.48 billion, a P/E ratio of 49.50, a price-to-earnings-growth ratio of 1.15 and a beta of 0.37. The firm’s 50 day simple moving average is $913.15 and its 200-day simple moving average is $807.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Loop Capital set a $950.00 price objective on Eli Lilly and Company in a research report on Monday, November 10th. Weiss Ratings raised shares of Eli Lilly and Company from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Leerink Partners raised Eli Lilly and Company from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $886.00 to $1,104.00 in a research note on Monday, November 10th. Finally, Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,087.32.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.